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OBJECTIVES: To assess the characteristics of SLE patients currently experiencing 
flares in Europe. METHODS: A multi-center retrospective medical chart review 
of adult (16-89 yrs) SLE patients was conducted in 1Q2014 among rheumatolo-
gists/internal medicine physicians in UK/France/Germany/Italy/Spain (5EU). 
Physicians were recruited from a geographically representative sample in each 
country. Approx. 5 consecutive eligible persistent active or relapse remitting SLE 
patients currently managed as part of usual care were identified within the study 
observation window. Physicians abstracted de-identified patient data on disease 
characteristics, lab values and treatment patterns. Patient disease status and 
humanistic burden was assessed by physician per clinical judgment & patient 
interaction. Patients experiencing a flare were identified for analysis. RESULTS: 
135 SLE patients who were experiencing flares were included in the analysis 
(UK:45/France:22/Germany:20/Italy:20/Spain:28). Mean age(yrs) was 5EU:40.6/
UK:44.4/France:39.3/Germany:36.9/Italy:41.0/Spain:37.9; % female was 5EU:78%/
UK:87%/France:59%/Germany:75%/Italy:70%/Spain:86%; % full-time employment 
was 5EU:33%/UK:20%/France:32%/Germany:30%/Italy:50%/Spain:43%; % part-time 
employment was 5EU:18%/UK:29%/France:9%/Germany:10%/Italy:10%/Spain:18%; 
% on sick leave was 5EU:17%/UK:9%/France:23%/Germany:25%/Italy:15%/
Spain:21%. Top-5 organ manifestations observed were musculoskeletal (5EU:88%/
UK:93%/France:100%/Germany:65%/Italy:95%/Spain:82%), mucocutaneous 
(5EU:85%/UK:96%/France:91%/Germany:65%/Italy:80%/Spain:82%), haematologic 
(5EU:56%/UK:56%/France:41%/Germany:60%/Italy:50%/Spain:68%), renal (5EU:33%/
UK:33%/France:23%/Germany:50%/Italy:45%/Spain:21%) and pulmonary (5EU:27%/
UK:38%/France:5%/Germany:10%/Italy:35%/Spain:32%). Percentage of patients 
with low C3 (5EU:73%/UK:55%/France:62%/Germany:85%/Italy:90%/Spain:89%), 
low C4 (5EU:78%/UK:59%/France:90%/Germany:90%/Italy:75%/Spain:89%) and 
positive anti-ds-DNA (5EU:90%/UK:80%/France:100%/Germany:95%/Italy:95%/
Spain:93%) were high. Among those with lab measures, mean ESR (mm/h) was 
5EU:50.1/UK:44.4/France:47.6/Germany:41.2/Italy:54.6/Spain:63.8; mean hemo-
globin (g/L) was 5EU:10.4/UK:9.8/France:11.1/Germany:10.5/Italy:10.5/Spain:10.7. 
Humanistic burden (reported via physician ratings, on a scale of 1 (most impact) 
to 7 (least impact)) was (mean scores): patient ability to perform every-day tasks 
- 5EU:4.4/UK:4.4/France:5.1/Germany:3.8/Italy:4.5/Spain:4.0; patient ability to 
interact fully with family and friends - 5EU:4.9/UK:4.9/France:5.5/Germany:4.2/
Italy:5.0/Spain:4.9; patient ability to work/keep employment - 5EU:3.9/UK:4.2/
France:4.2/Germany:2.8/Italy:4.2/Spain:3.7. Percentage of patients hospitalized 
> = 1 in the past-year was 5EU:56%/UK:40%/France:68%/Germany:65%/Italy:65%/
Spain:57%. CONCLUSIONS: SLE patients experiencing flares had significant clini-
cal and humanistic burden across the studied countries. Further scrutiny is war-
ranted to assess the modalities of care delivered to this patient group to alleviate 
their burden.
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OBJECTIVES: Orphan drugs are indicated for rare diseases and conditions. We 
assessed trends in approvals of new drugs with orphan indications in the US 
and in the prevalence of orphan drugs approved by the FDA from 1983 to 2014 
compared to non-orphan drug approvals in the same time frame METHODS: The 
study used regulatory and prevalence data derived from the US FDA, the European 
Medicines Agency (EMA), and other publicly available sources. Descriptive statis-
tics and the chi-square test were performed in the study. RESULTS: A total of 103 
BLAs and 799 NMEs were approved by the FDA from 1983 to 2014. The percentage 
of new drugs with orphan designation at approval was 43.7% for BLAs and 20.7% 
for NMEs (p< 0.001). Orphan drugs represented 13.9% of the new drugs approved 
from 1983 to 1989, 21.2% in the 1990s, 25.5% in the 2000s, and 33.8% from 2010 to 
2014. Information about the prevalence of disease was available for 73.7% of the 
orphan drugs. Indications approved for use in diseases with a prevalence of less 
than 1000 patients (i.e.: ultra-orphan drugs) represented 8.4% of all new orphan 
drugs. Ultra-orphan drugs represented 12.5%, 3.6%, 7.7%, and 15.8% of all orphan 
indications approved in the US from 1983-1989, 1990s, 2000s, and 2010-2014, 
respectively. CONCLUSIONS: This study found an increase in the percentage of 
drugs approved by the FDA for orphan diseases and conditions. Ultra orphan drugs 
revealed a greater increase over time than other orphan drugs as a proportion of 
all new drugs approved by the FDA. The limited innovation in diseases with large 
prevalence, the incentives provided by the Orphan Drug Act of 1982 and favorable 
reimbursement for orphan drugs in the US health care system may explain the 
increase in the approval of orphan drugs in the US.
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pain or bleeding completed a pain history and five PRO instruments (EQ-5D-5L, 
Brief Pain Inventory v2 [BPI], SF-36v2, International Physical Activity Questionnaire 
[IPAQ], and Hemophilia Activities List [HAL]) during routine clinic visits. To assess 
concordance of individual questionnaire items and correlation of domain/global 
scores using intraclass correlation coefficient (ICC), initial patients (target 125-150) 
were approached to complete the PROs at the end of their 3-4 hour visit in a simi-
lar non-bleeding state. RESULTS: From October 2013-October 2014, 381 patients 
enrolled; 164 (88% of initial 187) completed the retest. Median age of retest cohort 
was 33.9 years (Q1, Q3; 26.9, 46.0). Median time for completion of the initial survey 
with five PROs was 36.0 minutes and for the retest was 21.0 minutes. Median/mean 
time between tests was 1.5/1.6 hours. The majority of subjects had hemophilia 
A (74.4%) and were white-non-Hispanic (72.6%); 48.7% were married, 62.6% had 
some college or graduate-level education, 80.7% were employed, and 61.0% were 
overweight or obese. HCV was more common than HIV (49.4% vs 16.5%); 61.0% 
self-reported arthritis/bone/joint problems. Median/mean test-retest concord-
ance was: EQ-5D-5L, 80.0%/79.1%; BPI, 54.5%/58.9%; SF-36v2, 77.8%/76.4%; IPAQ, 
100%/100%; and HAL, 77.4%/75.9%. ICC for test-retest reliability were: EQ-5D-5L 
Health Index, 0.890; BPI–severity, 0.950; BPI–interference, 0.920; IPAQ total activity, 
0.940; SF-36v2 overall health, 0.910; HAL total score, 0.970. CONCLUSIONS: All five 
PROs are reliable in adult PWH. Therefore, the choice of instrument to be used for 
research or clinical care should be driven by instrument characteristics other than 
reliability.
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OBJECTIVES: Patient reported outcomes provide important information on the 
comprehensive impact of Systemic Lupus Erythematosus (SLE) on daily lives of 
patients. It also fosters patient physician communication, patient engagement and 
satisfaction with medical care. LupusPRO is a disease targeted patient reported 
outcome tool that has good measurement properties (Jolly et al., 2012) and has 
been validated in several countries. Herein we report the measurement properties 
of the Italian translation of the LupusPRO that was administered using a web based 
format. METHODS: LupusPRO was translated using forwards and back translation 
method into Italian language. It was pretested among 5 native Italian speaking 
subjects. As part of another study, 344 patients with SLE diagnoses were approached 
through the Patients organization network, asked to provide their demographics, 
medications and responses to the online LupusPRO. We evaluated internal consist-
ency reliability (ICR) of the LupusPRO domain items, floor-ceiling effects, known 
groups validity (KGV) and confirmatory factor analysis (CFA). ICR was tested using 
cronbach’s α . KGV was tested against current use of corticosteroids, with the hypoth-
esis that SLE patients currently on corticosteroids would have worse health status 
than without. Goodness of fit was evaluated in the CFA. RESULTS: Mean (SD) age 
and duration of disease were 39.7 (11.1) and 11.7 (9.3) yrs. Ninety one percent were 
women. Sixty four percent were on corticosteroids and sixty six percent were on 
hydroxychloroquine at the time of the study. ICR and Floor-ceiling effects were 
acceptable. The hypothesis about corticosteroids was supported for many subscales. 
On CFA, with few exceptions the items correlated highly (r> 0.5) with their hypoth-
esized scale. The CFI was 0.938 and TLI was 0.973 (> 0.9 is considered good model 
fit). The RMSEA was 0.093 (< 0.1 is considered acceptable model fit). CONCLUSIONS: 
Web version of LupusPRO Italian translation shows fair psychometric properties in 
Systemic Lupus Erythematosus patients.
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imProvement in HeaLtH-reLateD qUaLity of Life for SickLe ceLL 
DiSeaSe PatientS treateD witH cHemotHeraPy-free aLLogeneic 
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OBJECTIVES: Allogeneic hematopoietic stem cell transplantation (HSCT) can 
cure Sickle Cell Disease (SCD) but traditional chemotherapy-based conditioning 
regimens for HSCT are associated with substantial morbidity and mortality. The 
objective of this study was to determine if an innovative approach of chemo-
therapy-free, non-myeloablative HSCT with alemtuzumab is associated with 
improved health-related quality of life (HRQoL) in adult SCD patients. METHODS: 
Thirteen high-risk SCD patients underwent chemotherapy-free HSCT at a large 
urban academic medical center using human leukocyte antigen (HLA)-matched, 
related donors. Indications for transplantation in this cohort included frequent 
pain crises, stroke, and/or ≥ 2 lifetime episodes of acute chest syndrome. Generic 
HRQoL was assessed using the SF-36 in 9 patients who were assessed pre-HSCT 
and at 365 post-HSCT. Magnitude of effect was evaluated for SF-36 norm-based 
subscales and the SF-6D summary scores based on standardized response mean 
(SRM) (SRM> 0.5= medium; SRM> 0.8= large effect). RESULTS: Of 13 patients, all 
survived and 9 had completed 365 day post-HSCT assessments by time of analy-
sis. Mean change scores 365-day post-HSCT were 4.6 (SD 21.3) for physical func-
tioning (PF) (SRMPF= 0.2), 9.0 (SD 23.0) for role physical (RP) (SRMRP= 0.4), 17.1 
(SD 14.2) for bodily pain (BP) (SRMBP= 1.20), 18.6 (SD 16.0) for general health (GH) 
(SRMGH= 1.16), 15.2 (SD 10.5) for vitality (VT) (SRMVT= 1.45), 13.0 (SD 17.2) for social 
function (SF) (SRMSF= 0.76), 5.1 (SD 14.7) for role emotional (RE) (SRMRE= 0.34), 
5.7 (SD 9.8) for mental health (MH) (SRMMH= 0.59) and 0.21 (SD 0.13) forSF-6D 
index score (SRMSF6D= 1.66). CONCLUSIONS: Our pilot study demonstrated a 
large magnitude of improvement in HRQoL in terms of BP, GH, VT and overall 
health according to the SF-6D for SCD patients undergoing chemotherapy-free, 
non-myeloablative HSCT with alemtuzumab. These promising results, which are 
the first report of the impact of this innovative treatment on HRQoL in adults, war-
rant further investigation with more patients under treatment and longer-term 
follow-up.
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effects, only 3,424 prescriptions were reimbursed. Reimbursement per prescription 
varied by state; in 2001, the national average was $107. CONCLUSIONS: Despite an 
obesity epidemic, very few states reimbursed pharmacies for weight-loss medica-
tions, including orlistat. Understanding the different decisions that the states made 
with respect to weight-loss pharmacotherapy is a goal for future research.
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HyDrocoDone: a review of tHe LiteratUre
Hatfield M.D., Fleming M.L.
University of Houston, Houston, TX, USA
OBJECTIVES: An estimated 100 million adults suffer from chronic pain in the US. 
The total cost of pain ranges from $560 to $635 billion in 2010, exceeding that of 
heart disease ($309 billion), cancer ($243 billion), and diabetes ($188 billion). The 2011 
IOM report on pain states that effective pain management is “a moral imperative” 
for health care providers. Many pharmaceutical options are available to prescribers, 
most notably prescription opioids. Prescription opioids are analgesics which can 
be effective for the treatment of pain when monitored appropriately. Hydrocodone 
combination products are among the most commonly prescribed opioids in the 
US. The objective of this study was to perform a comprehensive literature review 
of the use and impact of hydrocodone in the US. METHODS: A comprehensive 
literature review was conducted regarding the use and impact of hydrocodone in 
the US. RESULTS: The US consumed 80% of the global supply of opioids and 99% 
of the global hydrocodone supply. From 1997 to 2007, hydrocodone use increased 
280%. Due to their potential for harm and abuse, hydrocodone combination prod-
ucts were recently rescheduled from Schedule III to Schedule II by the U.S. Food 
and Drug Administration (FDA). Single entity hydrocodone extended release was 
recently approved by the FDA and has been met with much controversy due to its 
potential for abuse. CONCLUSIONS: Hydrocodone use is highly prevalent in the 
US. Long-term use of hydrocodone and single entity hydrocodone use need to be 
actively monitored for appropriateness. Future studies should assess the impact 
of rescheduling.
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eStimation of meDicaL exPenDitUre aSSociateD witH oPioiDS USage in 
cHronic non-cancer Pain: a croSS-SectionaL StUDy baSeD on meDicaL 
exPenDitUre SUrvey anD PaneL Data
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OBJECTIVES: Chronic or long-term pain disturbs numerous lives, which is one of the 
most prevalent reasons for doctor visits and reduces people’s quality of life. A com-
mon treatment for long-term non-cancer pain (CNCP) is long-term opioid therapy. 
However, the effectiveness of opioids for CNCP is still controversy and associated 
medical expenditure is vague. We investigated the impact of opioid treatment on 
the total medical expenditures for U.S. general population. METHODS: We used 
the 2011 Medical Expenditure Panel Survey, a nationally representative survey for 
health care use, expenditures and health insurance coverage of the U.S. civilian non-
institutionalized population. After excluding individuals with the priority condition 
of cancer and current diagnosis of cancer, we used response to the SF-12 question-
naire and ICD codes to identify chronic pain conditions. The final sample includes 
11,858 individuals with 355 receiving opioid treatments. We conducted bivariate 
statistical analysis to compare demographic characteristics, clinical conditions and 
total expenditures for CNCP patients’ between on- and off-opioid treatment groups. 
Using a multivariate generalized linear model (GLM), we estimated the impact of 
opioid treatment on medical care expenditures for CNCP patients, after adjusting 
for covariates. RESULTS: The bivariate analysis results show statistical significant 
differences in the use of opioid treatments associated with race/ethnicity, education 
level, smoking status, physical activity, and health status. The unadjusted mean 
total annual medical expenditures were $29,914 for opioid users and $8,564 for 
non-opioid users. The GLM regression results show the opioid treatment is associ-
ated with $3,419 to $9,120 in additional medical expenditure, after adjusting covari-
ates. CONCLUSIONS: Appropriate management for CNCP is critical to improve their 
perceived health and wellbeing and to decrease medical expenditures. However, 
due to the cross-sectional design, there might be some higher spending for opioid 
users results from unobserved patient severity, as well as no treatment outcome 
measures, which needs further study.
PSy68
DoSing Pattern anaLySiS for bioLogicS in tHe treatment of PSoriaSiS 
in canaDa: inDication-SPecific information retrieveD from 
aDminiStrative cLaimS DatabaSe
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OBJECTIVES: High cost biologic treatments for diseases such as plaque psoriasis, 
raise growing concerns over the increasing cost to the health care systems that 
are funding these treatments. Administrative databases can generate important 
information about the way these drugs are prescribed in a “real world” setting. The 
objectives of this analysis were to determine the initial dosing and identify dose 
escalation patterns for biologics in the treatment of psoriasis in Canada. METHODS: 
A sample of data from patients covered by the public (Quebec and Ontario) and pri-
vate drug plans in Canada, who received a biologic between January 2010 and August 
2012 for at least 12 months, were retrieved (IMS Brogan, IMS Longitudinal Claims 
Dataset, Jan 2010 - Aug 2013, reported Nov 2013). A specific algorithm was developed 
based on prescriber information and concomitant medications to capture claims 
associated to psoriasis. Dosing analysis was performed for four biologics approved 
for psoriasis in Canada: adalimumab, etanercept, infliximab and ustekinumab. Dose 
escalation was defined as a 20% dose increase above the previous dose, excluding 
induction. RESULTS: A total of 4,510 patients were identified and met inclusion 
criteria. The average first year dose was higher than years 2 and 3, consistent with 
OBJECTIVES: Although opioids play a central role in the treatment, and palliation 
of many medical conditions, there is a large and growing problem of abuse nation-
ally and in South Carolina particularly. According to the 2009 National Survey on 
Drug Use and Health, more than 5 million Americans abused prescription opioid 
painkillers in January 2011. Reports show an increase in cases of doctor shopping, 
prescription forgery, illicit prescribing and dispensing, and other diversion activi-
ties. We determine patterns of opioid prescribing in South Carolina through an 
epidemiologic analysis and geo-spatial mapping of South Carolina prescription 
data for 2010-2011. METHODS: Using de-identified data from the South Carolina 
Reporting and Identification Prescription Tracking System (SCRIPTS), we conducted 
a state-wide epidemiological analysis of patient and prescriber opioid prescribing 
patterns including distributions of number of prescriptions, number of prescribers 
and of pharmacies used by each patient. Additionally, we conducted County- and Zip 
Code-level analyses of opioid prescribing patterns. RESULTS: Prescriber deciles were 
created representing 10% groupings of prescribers based on controlled substances 
(CS) II – IV prescription volume. The top 10% of SC prescribers wrote more than 60% 
(N= 2,158,574) of the total CS II – IV prescriptions in 2010, and 58% of total opioid 
prescriptions. The top pharmacy decile dispensed about 44% of total prescriptions 
and about 37% of opioid prescriptions. Five Zip Codes had the highest percent of 
opioid prescriptions out of total prescriptions (Charleston, Richland, Greenville, 
Barnwell and Aiken). In 2010 counties with the highest percent of prescriptions 
(> 61%) were Greenville, Richland, Barnwell and Charleston, whereas in 2011 the 
counties with the highest percent of prescriptions were Greenville, Chester, Richland 
and Charleston. CONCLUSIONS: Our findings indicate a relatively small percentage 
of providers, concentrated in a few counties, account for most opioid prescriptions. 
This group represents a potential target for physician education and engagement 
in handling pain management and appropriate use of opioids.
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OBJECTIVES: Many chronic users of immediate-release opioids (IROs) initiating 
treatment with extended-release opioids (EROs) are steered towards generic options, 
even if switching molecules is required. Switching may introduce uncertainty for 
patients regarding dosing, titration and efficacy. This study assessed treatment 
patterns among patients chronically-treated with IR oxycodone who initiate ERO 
treatment, and describes differences between patients initiating treatment on 
the same molecule and those who switch molecules. METHODS: Commercially-
insured patients aged < 65 were selected from de-identified OptumHealth Reporting 
and Insights claims data, 2011-2014. Chronic IR oxycodone users were defined as 
patients with ≥ 2 continuous prescriptions and ≥ 60 days supply leading up to initia-
tion of ERO treatment (index). Patients were excluded if they had claims for EROs 
during a 6-month baseline period or possible opioid replacement therapy (metha-
done/buprenorphine) during the 6-month follow-up period, and were required to 
be continuous users of opioids throughout follow-up. The sample was stratified 
based on whether ER therapy was initiated on the same molecule (ER oxycodone) 
or different molecules. Treatment patterns and pill count were assessed for both 
cohorts. RESULTS: During baseline, 2,318 chronic IR oxycodone users initiating 
EROs were identified, with 933 (40%) initiating ER oxycodone and the remainder 
switching molecules. Same-molecule patients were more likely to continuously 
use index therapy (41.9% vs. 33.6%), and less likely to switch to a different ERO 
(12.3% vs. 26.0%). Among different-molecule patients switching EROs, nearly half 
switched to ER oxycodone. Concomitant use of IR oxycodone was observed in both 
groups, but continuous index ERO users in the same-molecule cohort saw a greater 
decline in IR pill count compared with the different-molecule cohort (-173.3 vs. 
-105.9). CONCLUSIONS: Chronic IR oxycodone patients initiating EROs on the same 
molecule were more likely to remain on index treatment, and those remaining on 
treatment experienced a greater decline in IR oxycodone pill count.
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OBJECTIVES: More than one third of adults in the U.S. are considered obese (body 
mass index ≥ 30kg/m2). Because of their relatively low socioeconomic status, the 
Medicaid population is disproportionately affected by obesity. The objective was to 
compare the utilization of and spending on anti-obesity medication, specifically 
orlistat (amphetamine-based weight-loss drugs were highly restricted by Medicaid 
because of their potential for abuse), by state Medicaid programs from 1999-2013. 
Orlistat, approved by the FDA in April 1999, is a gastric and pancreatic lipase inhibi-
tor that reduces dietary fat absorption. METHODS: Using the individual state files 
for Medicaid outpatient drug utilization maintained by the Centers for Medicare 
and Medicaid Services, quarterly utilization and (pre-rebate) expenditure data 
from 1999-2013 were extracted for all branded and generic orlistat prescriptions 
for Medicaid beneficiaries. Descriptive statistics were computed. RESULTS: In 1999, 
North Carolina reimbursed 5,242 prescriptions; Louisiana 3,712 prescriptions; and 
Wisconsin 1,460. Subsequently, several other states, such as California, Connecticut, 
Kentucky, Minnesota, New Jersey, and Pennsylvania came on board with a fairly large 
number of prescriptions reimbursed (6,041 in California in 2003). In other states, like 
Ohio and New York, no orlistat prescriptions were reimbursed until the last years of 
the study, most likely representing a policy shift. In 2001,when Medicaid utilization 
was at its peak, a total of 87,811 prescriptions were reimbursed across the country. 
By 2013, due to several factors including an over-the-counter version of orlistat 
approved by the FDA in 2010 and a loss in popularity due to gastrointestinal side 
